Semaglutide
What to know about Semaglutide
Semaglutide acts on a hormone signal called GLP-1, which helps control appetite and blood sugar. Approved products have been studied in large human trials and monitored after approval.
- How it may work
- GLP-1 receptor activation increases glucose-dependent insulin release, lowers glucagon when glucose is elevated, slows gastric emptying, and affects appetite signalling.
- What research found
- In STEP 1, 1,961 adults were randomized for 68 weeks; average weight change was -14.9% with semaglutide 2.4 mg and -2.4% with placebo, alongside lifestyle support.
- What is not settled
- Stomach and gut side effects are common. Approved product instructions explain who should not use them, warning signs, dose changes and follow-up. Those instructions do not establish the safety of an unverified research product.
- Research and product status
- Semaglutide has licensed U.S. products for specific uses. Brand, formulation, route, and labelled use matter.
Research reference
- Research amount range
- 0.25–2.4 mg per administration — not a starting amount
- Reference frequency
- Once a week — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Reported timing context
- Once weekly on the same day; time of day is flexible.
- What people report
- Appetite changes are often noticed within the first weeks; dose is escalated slowly.
- Model accumulation timescale
- ~35.0 days — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
- Reported course context
- titrated over months
- Reported break context
- n/a — titrated, not cycled Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- STEP 1 measured weight change over 68 weeks, including 16 weeks of gradual dose increases. Its weight-loss result describes that longer period, not how someone felt after the first dose.
- When to assess
- The first weeks focus on gradual dose increases and checking side effects. Agree a goal and check-in plan with your provider. Judge progress after enough time at a regular dose you can tolerate, using the current product instructions.
- Conditions and limitations
- The pivotal study included lifestyle support. The evidence does not require a special injection time or fasting, but it does depend on the licensed formulation, schedule, and participant context.
- When to stop
- Ask your prescriber when to stop, especially if stomach or gut side effects are severe or do not settle, or you notice other warning signs in the product instructions. A slow start on the scale is not a reason to take more.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about Semaglutide alongside other compounds or medicines.
Key properties
- Formula
- C187H291N45O59
- Mol. weight
- 4,113.64 Da
- CAS
- 910463-68-2
- PubChem CID
- 56843331
External references
Vial arithmetic
Published research contexts for Semaglutide describe 0.25–2.4 mg per administration. Descriptive only, not a recommendation.
Research schedule reference
Reported schedule context for Semaglutide; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Starting step to limit gastrointestinal effects; not intended for a glucose effect yet. | 0.25 mg | Once weekly | SubQ |
| Weeks 5–8 | 0.5 mg | Once weekly | SubQ |
| Weeks 9–12 | 1 mg | Once weekly | SubQ |
| Weeks 13–16 | 1.7 mg | Once weekly | SubQ |
| Week 17+Highest commonly-reported step; step up no sooner than every 4 weeks and only as tolerated. | 2.4 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.98× single dose
- Time to steady state
- 35.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- STEP 1 (Wilding et al., NEJM 2021)Weekly semaglutide escalated to 2.4 mg over 16 weeks in obesity research.